X

The ASCO Post

The ASCO Post
SECOMBIT Trial Evaluates Optimal Treatment Sequencing in BRAF-Mutated Melanoma

Patients with untreated metastatic BRAF-mutated melanoma may benefit from receiving immunotherapy first, then moving to targeted therapy suggests the randomized, phase II SECOMBIT trial.

The ASCO Post
10/22/2021
Risk-Based Treatment of Pediatric and Young Adult Synovial Sarcoma

Risk-based treatment of pediatric and young adult patients with synovial sarcoma produced favorable outcomes in those with nonmetastatic disease.

The ASCO Post
10/22/2021
Second-Line Sotorasib Plus Afatinib for KRAS–Mutant NSCLC

Combination KRAS inhibitor sotorasib with afatinib, a pan-ErbB tyrosine kinase inhibitor, was feasible in treating patients with NSCLC and mutated KRAS...

The ASCO Post
10/18/2021
Characteristics of Genomically Targeted Single-Patient Use Requests for Pediatric Cancers

Scientists analyzed characteristics of genomically targeted single-patient use requests for investigational agents for the treatment of pediatric cancers.

The ASCO Post
10/15/2021
Adjuvant Pembrolizumab Shows Efficacy in High-Risk Stage II Melanoma in Adults and Children Older Than 12

According to a late-breaking interim analysis of the phase III KEYNOTE-716 trial, adjuvant pembrolizumab reduced the risk of recurrence in adults and children older than age 12...

The ASCO Post
10/11/2021
Ensartinib Shows Superior Efficacy to Crizotinib in Advanced ALK-Positive NSCLC

The eXalt3 trial has shown significantly prolonged progression-free survival with ensartinib vs crizotinib in patients with advanced, recurrent, or metastatic ALK-positive NSCLC...

The ASCO Post
10/10/2021
Factors Associated With Risk of Hearing Loss in Pediatric Patients Receiving Radiation and Chemotherapy

This study explores factors associated with an increased risk of hearing loss in pediatric patients receiving radiation therapy and chemotherapy for central nervous system and head and neck tumors.

The ASCO Post
10/06/2021
FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory B-Cell Precursor ALL

The FDA approves brexucabtagene autoleucel, a CD19-directed CAR T-cell therapy, for adult patients with relapsed or refractory B-cell precursor ALL.

The ASCO Post
10/04/2021
Poziotinib, a Tyrosine Kinase Inhibitor, for HER2 Exon 20–Mutant NSCLC

Scientists explore poziotinib, an irreversible covalent tyrosine kinase inhibitor thats smaller size and greater flexibility may allow the drug to circumvent steric hindrance...

The ASCO Post
09/29/2021
Maintenance Daratumumab After Initial Therapy for Newly Diagnosed Multiple Myeloma

Scientists significantly prolonged progression-free survival with maintenance daratumumab vs observation following induction and consolidation with or without daratumumab in addition to ASCT...

The ASCO Post
09/28/2021
Subscribe to The ASCO Post

source list reference

rgb(171, 222, 222)
#7d60d9
#2694a4
#32a887
200, 66, 245
#85eb24
rgb(195, 2, 230)
#352625
#4d4537
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
#d2093c
#8e3f1c
rgb(242, 0, 137)
#76b6c3
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
#bfcfc8
rgb (252, 186, 3)
#c61417
rgb(156, 242, 7)
#67e25b
#efef71
#03cffc
rgb(224, 4, 129)
#42fc9a
rgb(80, 147, 199)
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
rgb(5, 235, 235)
#e7f6e3
#6fc969
#9a8c2c
#a9c507
rgb(235, 190, 9)
#2b9ab3
#e61923
rgb(209, 227, 11)
#990677
#4a7bab
200, 66, 245
#89f67c
#49a21d
rgb (132, 101, 173)
#2c990a
#d7da81
#f5ce42
rgb(217, 7, 192)
#575662
#a60538
rgb(2, 230, 230)
#49cde9
#c20fce
rgb(80,199,199)
#d95d39
#eb5834